1. European Medicines Agency (EMA). Benefit-risk methodology project. Work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment. EMA/549682/2010 - Revision 1, 2010. Available at https://www.ema.europa.eu/en/documents/report/benefit-risk-methodology-project-work-package-2-report-applicability-current-tools-processes_en.pdf (accessed on 29/08/2019).
2. A framework for organizing and selecting quantitative approaches for benefit-harm assessment;Puhan;BMC Med Res Methodol,2012
3. Using outcomes to analyze patients rather than patients to analyze outcomes: a step toward pragmatism in benefit:risk evaluation;Evans;Stat Biopharm Res,2016
4. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity;Lotrionte;Am J Cardiol,2013